AstraZeneca and AgPlus present clinical data at ERS 2017

AstraZeneca and AgPlus Diagnostics present clinical data from a novel, 10 minute, electrochemical point of care assay system for the measurement of Eosinophil Derived Neurotoxin (EDN) at ERS 2017

AgPlus and AstraZeneca have worked together to develop a novel point of care test (based on AgPlus’ patented electrochemical immunoassay platform technology) for EDN and have reported the results from a successful pilot clinical study at ERS 2017. A copy of the poster is now available here: ERS 2017 AgAZ poster.

Increased blood eosinophils (EOS) are associated with increased exacerbations, disease severity and mortality in asthma. EDN is an alternative biomarker of eosinophilia that may better reflect eosinophil activity than EOS. EDN can be measured by immunoassay but a clinical diagnostic is not available. In this study, a prototype point of care assay system for the detection of EDN was assessed using a 20ul sample of venous blood, capillary blood or plasma from 10 patients recruited on their historical eosinophil levels to represent a wide range.

The key conclusions of the study were:

  • EDN was measurable in capillary blood, venous blood and plasma with the novel point-of-care electrochemical immunoassay platform giving a result in under 10 minutes.
  • The measured EDN levels were highly correlated to blood eosinophils.
  • EDN may be an alternative biomarker of eosinophilic asthma to EOS and is amenable to rapid, point of care diagnostic technology and since EDN release is an active process that can be triggered by inflammatory mediators, EDN may reflect active pathology in eosinophilic asthma better than eosinophil counts.

About AgPlus Diagnostics Ltd:

AgPlus Diagnostics has developed a diagnostic platform technology that delivers the market requirement of a true fully quantitative PoC test for use across a wide range of clinical applications. The technology, developed for OEM Business-to-Business solutions, provides clients with a customised assay system for rapid PoC diagnostics. The platform can be used across multiple applications and sectors where faster diagnostic results will enable users to make critical decisions in minutes.

For more information please visit www.agplusdiagnostics.com or e-mail info@agplusdiagnostics.com

About AstraZeneca:

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.


AgPlus Diagnostics is Awarded Innovate UK Funding

AgPlus Diagnostics is Awarded Innovate UK Funding

13th June, 2017 – Bedford, UK.

AgPlus Diagnostics, the quantitative point-of-care diagnostic test company, has recently been awarded its first Innovate UK grant. This was awarded as part of Innovate UK’s Analysis for Innovators competition. AgPlus will use the funding to collaborate with the UK’s National Physical Laboratory (NPL) on a project to develop and refine the manufacturing of key AgPlus cartridge components.

‘AgPlus is delighted to receive this award and to partner again with NPL.’ said Christopher Getley, AgPlus’s Chairman, ‘It forms an important part of AgPlus’s current manufacturing scale-up plan in order to meet the 2018 launch of our first human clinical diagnostic test.’

The AgPlus clinical diagnostic test platform utilises electrochemical immunoassay technology in a patented microfluidic cartridge format. It is a truly point-of-care platform consisting of a handheld reader and single use cartridges. The unique electrochemical signalling and measurement system allows fully quantitative, extremely sensitive and accurate results to be obtained in under 10 minutes. AgPlus is a business-to-business company that has, over the last 12 months, built key relationships with both pharmaceutical and diagnostics companies.

About AgPlus Diagnostics Ltd.

www.agplusdiagnostics.com

The demand for quantitative Point of Care (PoC) testing is increasing, driven by the goal of Personalised Healthcare where patients are matched with the right treatment at the right time using their individual biomarker profiles. AgPlus Diagnostics has developed a diagnostic platform technology that delivers the market requirement of a true fully quantitative PoC test for use across a wide range of clinical applications. The technology, developed for OEM Business-to-Business solutions, provides clients with a customised assay system for rapid PoC diagnostics. The platform can be used across multiple applications and sectors where faster diagnostic results will enable users to make critical decisions in minutes. The AgPlus ADVANTAGETM platform is market ready and AgPlus has a strong client product pipeline.

For further information, please contact:

Dr Nanette Bartram, Director, Business Development

E: nanette.bartram@agplusdiagnostics.com or T: +441234 867100

About NPL
The National Physical Laboratory (NPL) is the UK’s National Measurement Institute and the birthplace of Alan Turing’s ACE computer, the first universal computer of its kind; packet switching, the basis of the internet; and atomic time, the backbone of GPS and global communications.

Our measurement expertise has underpinned prosperity and quality of life in the UK for more than a century. Our role is highly diverse and finds us working on world-leading science and engineering that impacts healthcare, environmental monitoring, advanced manufacturing and the development of next-generation technologies and techniques, with the potential to further transform our lives; from new antibiotics to tackle resistance and more effective cancer treatments, to unhackable quantum communications and superfast 5G.

Based in Teddington, south-west London, NPL employs over 500 scientists and is home to 388 of the world’s most extensive and sophisticated measurement science laboratories.

 About Innovate UK Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy
For further information visit www.innovateuk.gov.uk


Rainbow Seed Fund Invests in AgPlus Diagnostics

Rainbow Seed Fund, an early-stage venture capital fund focused on promising technologies developed at the UK’s largest publicly-funded research facilities and campuses, today announces its investment into AgPlus Diagnostics, a technology platform developed by scientists at the UK’s National Physical Laboratory (NPL).

The AgPlus platform is based on research conducted at Rainbow partner NPL, the UK’s National Measurement Institute, a world-leading centre in developing and applying the most accurate measurement standards available.

Dr Andrew Muir, Investment Director for the Rainbow Seed Fund, said ” Fast, accurate and affordable measurement is critical to getting it right in the point-of-care market, so AgPlus’ National Physical Laboratory origins are the perfect pedigree. Testament to this are the company’s successful feasibility projects in a wide range of applications and the ongoing commercial engagement.”

Full text of press release available here: AgPlus RSF Funding Release 160928


AgPlus Diagnostics to Develop Point-of-Care Test for AstraZeneca

AgPlus Diagnostics Ltd today announced that they have signed a contract with AstraZeneca to develop a prototype diagnostic. The agreement will cover AgPlus Diagnostics developing a diagnostic assay for potential use as part of a personalised approach to treating respiratory disease.

Keith Page, CEO of AgPlus Diagnostics, said “This is a great new collaboration for AgPlus and recognises the strength of the AgPlus technology and the strength of healthcare development in the UK. AgPlus sees itself as a leading innovator in new technology for diagnostics and is proud to be associated with AstraZeneca, a global leader in biopharmaceuticals.”

AgPlus’ platform technology combines novel electrochemistry and metallic nanoparticles signaling with diagnostic immunoassays to provide high sensitivity and fully quantitative analyte detection. It is anticipated that the AgPlus ADVANTAGETM handheld portable reader and single use test cartridge may be utilised in primary care settings to assist physicians with treatment decisions.

If successful, the prototype device could potentially be developed into a commercial product to accompany AstraZeneca’s respiratory product portfolio.

Ruth March, VP and Head of AstraZeneca Personalised Healthcare & Biomarkers, said “Through this partnership, we hope to make available a quick and innovative point-of-care diagnostic to respiratory patients through their physicians. If successful, this diagnostic could be used to measure several biomarkers, which would support our goal of matching patients with the right treatment using their individual biomarker profiles.”

Full text of Press Release can be downloaded here: AgPlus Diagnostics to Develop Point of Care Test for AstraZeneca 21st Sept 2016


Veterinary Team at ZSL Whipsnade Zoo and AgPlus Diagnostics Collaborate

Veterinary Team at ZSL Whipsnade Zoo and AgPlus Diagnostics Collaborate On Innovative Method To Monitor Asian Elephants During Pregnancy

SG9A8583 ZSL Elizabeth.jpg

The veterinary team at ZSL, a world leader in elephant conservation and science, are working with AgPlus Diagnostics Ltd to develop a specific, point of care immunoassay system capable of monitoring pregnancy in elephants on-site at ZSL Whipsnade Zoo. In the first trial of its kind, the ZSL team together with scientists at AgPlus used the newly developed system to monitor the progesterone levels of Karishma, one of Whipsnade’s Asian elephants and part of the European Endangered species Programme (EEP), during her recent pregnancy prior to the birth of her calf Elizabeth.  If the trial is successful it is hoped that AgPlus will be able to provide ZSL (and other collections with breeding programs) customised, hand held, portable diagnostic systems for on-site measurements allowing tailored animal care as well as saving time and cost.

If you would like to help ZSL in their mission to protect endangered wildlife please contact: Sandra Crewe, Head of Corporate Partnerships, Zoological Society of London sandra.crewe@zsl.org

For more information on the AgPlus Progesterone Test and the Point of Care diagnostic platform please contact info@agplusdiagnostics.com